background figure 1 background figure 2


Sep, 29, 2023

Regel Therapeutics Awarded $1 Million from HS Chau Women in Enterprising Science Program at the Innovative Genomics Institute to Continue Developing its Gene Modulation Technology.

CAMBRIDGE, Mass. and BERKELEY, Calif., September 29th, 2023 /PRNewswire/ -- Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to modulate gene expression, today announced that based upon the groundbreaking work of its Co-Founder and Chief Scientific Officer Dr. Navneet Matharu it has been selected to receive $1 Million in...

Mar, 16, 2023

Regel Therapeutics announces its participation at the Dravet Syndrome Conference and attendance at the European Dravet Syndrome Advanced Therapies Meeting in Madrid, Spain on March 23rd and 24th 2023.

CAMBRIDGE, Mass., and BERKELEY, Calif March 16th 2023 / PRNewswire -- Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene expression, today announced that Jordane Dimidschstein, Ph.D., co-founder and COO, will present Regel’s technology and pipeline at the Dravet Conference...

Jan, 27, 2023

Regel Therapeutics launches its website and welcomes Andrew Schiermeier to its Board of Directors.

Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website, expands its Board of Directors and announces its Scientific Advisory Board. The company launches its website with key pipeline information Regel adds industry leader Andrew Schiermeier, Ph.D to its Board of Directors Regel announces its Scientific...

Page 1 of 1